Search the webpage

Created by Simon Kaja on   July 11, 2018   in category: Scientific publications

Trabodenoson, an alpha1 adrenergic agonist, shows preclinical efficacy in a preclinical model for dry eye syndrome, according to a study co-authored by Experimentica Ltd.

According to the results of a study published in the June 2018 issue of Investigative Ophthalmology and Vision Research, trabodenoson eye drops reduced attenuated hallmark signs of dry-eye disease pathology, including corneal surface inflammation, lacrimal gland infiltration by immune cells and loss of mucin-producing goblet cells in the conjunctiva.

The study, conducted in collaboration with Inotek Pharmaceuticals Corp., K&P Scientific LLC and Loyola University Chicago, compared the preclinical efficacy with a marketed formulation of ophthalmic cyclosporine emulsion and concluded that trabodenoson showed similar or better preclinical efficacy, supporting the development of A1R-targeting pharmaceuticals for DED.

Experimentica Ltd. is a global contract research organization specialized in ocular models. Headquartered in Kuopio, Finland, Experimentica Ltd. focuses on Advancing Ophthalmic Drug DiscoveryTM by offering an industry-leading portfolio for ophthalmic drug development.

Contact for media enquiries: 

Dr. Simon Kaja
Chief Scientific Officer
Experimentica Ltd.
Phone: +1 (844) 393-49393
Email: kaja@experimentica.com

Leave a Comment

LATEST NEWS

Check out our new publication on the mouse dry-eye disease model

An alpha1 adrenergic agonist shows preclinical efficacy in a preclinical model for dry eye syndrome ... Read More

Meet Us at ARVO 2018

News
Email info@experimentica.com to set up a One-on-One meeting ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!